QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:BPMC

Blueprint Medicines - BPMC Stock Forecast, Price & News

$48.51
-1.68 (-3.35%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$48.00
$50.11
50-Day Range
$41.06
$67.91
52-Week Range
$40.78
$111.78
Volume
510,618 shs
Average Volume
763,388 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.67

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
72.5% Upside
$83.67 Price Target
Short Interest
Bearish
7.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Blueprint Medicines in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$258,115 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($9.23) to ($9.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

604th out of 1,023 stocks

Pharmaceutical Preparations Industry

293rd out of 501 stocks

BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

Robert W. Baird Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)
9 Analysts Have This to Say About Blueprint Medicines
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
10/27/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/15/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$83.67
High Stock Price Forecast
$122.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+72.5%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$-644,090,000.00
Net Margins
-263.54%
Pretax Margin
-261.03%

Debt

Sales & Book Value

Annual Sales
$180.08 million
Book Value
$16.50 per share

Miscellaneous

Free Float
57,785,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.62

Key Executives

  • Mr. Jeffrey W. Albers J.D.Mr. Jeffrey W. Albers J.D. (Age 51)
    M.B.A., MBA, Exec. Chairman
    Comp: $1.38M
  • Ms. Kathryn Haviland (Age 46)
    Pres, CEO & Director
    Comp: $786.39k
  • Mr. Alexis A. Borisy A.M. (Age 50)
    Co-Founder & Director
    Comp: $46.64k
  • Mr. Michael Landsittel (Age 50)
    Chief Financial Officer
    Comp: $679.05k
  • Dr. Percy H. Carter M.B.A. (Age 51)
    Ph.D., Chief Scientific Officer
    Comp: $761.15k
  • Dr. Fouad Namouni M.D.Dr. Fouad Namouni M.D. (Age 53)
    Pres of R&D
    Comp: $986.52k
  • Ms. Christina RossiMs. Christina Rossi (Age 46)
    Chief Operating Officer
  • Dr. Christopher K. Murray (Age 59)
    Sr. VP of Technical Operations
  • Jenna Cohen
    Sr. Director & Head of Investor Relations
  • Ms. Tracey L. McCain Esq. (Age 54)
    Exec. VP, Chief Legal & Compliance Officer and Sec.













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 5 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BPMC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BPMC, but not buy additional shares or sell existing shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

15 brokers have issued 1-year target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $40.00 to $122.00. On average, they predict the company's share price to reach $83.67 in the next twelve months. This suggests a possible upside of 72.5% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2022?

Blueprint Medicines' stock was trading at $107.11 at the start of the year. Since then, BPMC shares have decreased by 54.7% and is now trading at $48.51.
View the best growth stocks for 2022 here
.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 4,240,000 shares, an increase of 15.8% from the October 31st total of 3,660,000 shares. Based on an average trading volume of 723,500 shares, the short-interest ratio is currently 5.9 days. Approximately 7.3% of the company's shares are sold short.
View Blueprint Medicines' Short Interest
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) issued its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($2.00) EPS for the quarter, missing the consensus estimate of ($1.63) by $0.37. The biotechnology company had revenue of $24.19 million for the quarter, compared to the consensus estimate of $42.58 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 56.45% and a negative net margin of 263.54%. The firm's revenue for the quarter was down 96.8% compared to the same quarter last year. During the same quarter last year, the company earned $11.16 earnings per share.

What guidance has Blueprint Medicines issued on next quarter's earnings?

Blueprint Medicines issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.00 million-$200.00 million, compared to the consensus revenue estimate of $191.21 million.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.62%), Vanguard Group Inc. (9.46%), Price T Rowe Associates Inc. MD (6.74%), State Street Corp (3.71%), Cadian Capital Management LP (2.44%) and Alliancebernstein L.P. (2.36%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Marion Dorsch, Mark Alan Goldberg, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $48.51.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.90 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644,090,000.00 in net income (profit) each year or ($12.10) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 12/6/2022 by MarketBeat.com Staff